Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06124066
Other study ID # 583/UN4.6.4.5.37/PP36/2022
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 1, 2022
Est. completion date October 30, 2022

Study information

Verified date November 2023
Source Hasanuddin University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Double J stent (ureteral stent) can cause discomfort to patients, generally due to irritation of the bladder mucosa, especially in the trigone area, smooth muscle spasm, and reflux of urine into the ureter. Complaints often appear in patients, especially lower urinary tract symptoms (LUTS), pain in the waist when urinating due to reflux of urine, sexual dysfunction, and hematuria. Currently, to assess complaints after ureteral stent placement, the Ureteral Stent Symptom Questionnaire instrument consists of 6 topics: urinary complaints, pain, general health, work, sexual problems, and other things. Interleukin-6 is an important inflammatory cytokine when irritation occurs after ureteral stent placement. Interleukin 10 is a cytokine with potent anti-inflammatory properties that plays a central role in limiting the host's immune response to pathogens, thereby preventing host damage and maintaining normal tissue homeostasis. The profile of these biomarkers has the potential to determine the correct prognosis and therapy. Mirabegron is a β3 adrenergic receptor agonist that has a dual antioxidant effect that plays a key role in the first step of the antimicrobial response and early resolution of inflammation so that post-stent complaints similar to overactive bladder complaints can be resolved. Tamsulosin (a selective α1A- and α1D-adrenoceptor antagonist) has a relaxing effect on the smooth muscle in the prostate, the neck of the bladder, and the distal ureter, thereby reducing the inflammatory reaction and improving oxidative stress by reducing the formation of reactive oxidative stress.


Description:

The research design used was experimental with randomized sampling, double-blinded, in men and women with ureteral stents. The patient signed informed consent regarding blood and urine sampling, bladder mucosal biopsy, placement and removal of ureteral stents, drug administration, and side effects of therapy. The history and physical examination of the patient were recorded including age, height, weight, and body mass index (BMI). Investigation procedures for urinalysis, routine blood, SGOT/SGPT, urea/creatinine, blood sugar during, ultrasonography, plain abdominal photos, and CT scan urography were performed on patients before surgery. The patient's largest stone size is used as a benchmark to record the patient's stone size. All patients who underwent routine post-ureterorenoscopy lithotripsy (URSL) ureteral stent procedures and met the inclusion and exclusion criteria were included in the study evaluation. The ureteral stent used was 4.7 Fr in size with a length of 24-26 cm, made from polyurethane used in all patients. Blood and urine samples will be taken before drug administration begins, and when the ureteral stent is removed or replaced. Bladder mucosal biopsy was performed in the trigone vesicae around the contralateral ureteral opening during cystoscopy before ureteral stent placement, and on the ipsilateral side when the ureteral stent was to be removed or replaced in the 6th week after ureteral stent placement. A plain photo of the abdomen or ultrasound is done postoperatively to see the remaining stone fragments and the position of the ureteral stent. Urethral catheters were removed on the 2nd postoperative day in all patients before the patients were discharged and given oral antibiotics (cefadroxil) for 5 days. During the observation phase, the patient was given the same analgesic (paracetamol 500 mg every 8 hours/24 hours and if needed can be given every 6 hours/24 hours). The total amount of analgesics consumed by the patient will be recorded in filling out the final questionnaire. Patients were asked to come to the urology clinic at the hospital for control on the seventh day. The patient will be given a questionnaire format that will measure the presence or absence and severity of side effects experienced by the patient for 7 days after ureteral stent placement. Patients will be divided into 3 groups of drug administration. The double-blinded method is used to minimize bias. All medicines were placed in the same 3 boxes, which were held by the paramedics so that the patients and researchers did not know the allocation of the types of drugs given. All patients have been informed about the side effects of the drug. Administration of mirabegron 50 mg/day compared to tamsulosin 0.4 mg and placebo began on the third day before insertion of the ureteral stent. Completion of the questionnaire began on the seventh day after ureteral stent insertion, then it was measured every 7 days (7th, 14th, 21st, 28th, 35th, and 42nd day) after ureteral stent insertion. Filling out the questionnaire can be done by in-person interview at the clinic or by telephone.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date October 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Patient with first ureterorenoscopy and ureteral stent placement - Using a semi-rigid (rigid) retrograde or flexible (flexible) ureteroscope - Stent placement on one side - Stent installation size 4.7 Fr, length 24-26cm hydrophilic coated ureteric stent - Patients who can read and understand Indonesia language (Bahasa Indonesia) Exclusion Criteria: - Patients with or who have a history of malignancy of the urinary tract - Patients with LUTS caused by benign prostatic enlargement, bladder stones, or urethral strictures - Catheterized patients or on self-catheter therapy regularly and patients with urinary diversion - Patients with Post void residual volume > 350 mL - Patients with neurogenic bladder and/or OAB syndrome, stress incontinence, or mixed stress/urge incontinence - Patients with chronic pain that is not controlled or on therapy to manage chronic pain - Patients with symptomatic UTI - Patients with a prior history of sexual dysfunction - Have or are currently undergoing radiation therapy/hormonal therapy and/or surgical procedures in the minor pelvis, ureteral reconstructive surgery. - Patients with primary neurological disorders, such as multiple sclerosis, Parkinson's disease, diabetic nephropathy, or other neurological diseases that affect bladder function. - Patients who are hypersensitive to mirabegron and tamsulosin or their derivatives and patients with mirabegron and tamsulosin contraindications. - The patient could not follow the research protocol due to an organic brain disorder or psychiatric disorder - Patients with autoimmune diseases and other inflammatory diseases, as well as patients taking immunosuppressant drugs

Study Design


Intervention

Drug:
Mirabegron 50 MG
The participants were given mirabegron 50 mg or tamsulosin 0.4 mg and filled in the Ureteral Stent Symptom Questionnaire (USSQ), filled in directly when the patient arrived or by telephone.

Locations

Country Name City State
Indonesia DR Wahidin Sudirohusodo Hospital, Hasanuddin University Hospital, and Akademis Jaury Jusuf Putra Hospital. Makassar South Sulawesi

Sponsors (1)

Lead Sponsor Collaborator
Hasanuddin University

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary serum and urine Interleukin-6 serum level (ELISA) Interleukin-6 serum level Pre-intervention and immediately after the intervention
Primary serum and urine Interleukin-10 serum level (ELISA) Interleukin-10 serum level Pre-intervention and immediately after the intervention
Primary Histopathology The severity of the mucosal inflammatory reaction was graded using a semiquantitative scale where 0=none, 1 = focal lymphocytic infiltration, 2 =diffuse predominantly lymphocytic infiltration, 3 =diffuse predominantly eosinophil polymorphonuclear infiltration and 4 = grade 3 changes in combination with intra-epithelial eosinophilic micro-abscesses. Pre-intervention and immediately after the intervention
Primary Urinary symptoms in the Ureteral Stent Symptom Questionnaire (USSQ) parameter Minimum values 2 and maximum values 47 Pre-intervention, immediately after the interventio, and up to 4 weeks
Secondary Basis data Characteristic data participants pre-intervention
See also
  Status Clinical Trial Phase
Completed NCT02547805 - Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days Phase 2
Completed NCT02579161 - Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy Phase 3
Completed NCT01187745 - Study to Look for Artifact on Computed Tomography (CT) Representing Kidney Stones N/A
Withdrawn NCT00875823 - International Registry for Primary Hyperoxaluria N/A
Completed NCT05519150 - Donors With Nephrolithiasis at the Time of Transplant Evaluation (DONATE). Long Term Follow-up.
Recruiting NCT02522689 - Comparison of Ultra-mini PCNL and Micro PCNL N/A
Recruiting NCT01514032 - Extracorporal Shockwave Lithotripsy Versus Retrograde Intrarenal Surgery for the Treatment of Kidney Stones N/A
Completed NCT00873054 - Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy N/A
Completed NCT00765128 - Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy Phase 4
Withdrawn NCT00583258 - A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones N/A
Active, not recruiting NCT03630926 - Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Not yet recruiting NCT02214836 - Ultrasound Imaging of Kidney Stones and Lithotripsy N/A
Completed NCT03095885 - A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria N/A
Completed NCT01088555 - Effect of Sodium Thiosulfate on Urine Chemistries of Hypercalciuric Stone Formers N/A
Completed NCT01330940 - Effect of Diet Orange Soda on Urinary Lithogenicity N/A
Recruiting NCT00489723 - Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ? N/A
Recruiting NCT05417568 - Oxalate-Driven Host Responses in Kidney Stone Disease N/A
Recruiting NCT02375295 - Struvite Stones Antibiotic Study Phase 4
Enrolling by invitation NCT02408211 - Preoperative Antibiotic PNL Study Phase 4
Withdrawn NCT01560091 - Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Phase 3